Lukas Flatz - Hookipa Pharma CoFounder
| HOOK Stock | USD 2.15 0.15 6.52% |
Insider
Lukas Flatz is CoFounder of Hookipa Pharma
| Address | 350 Fifth Avenue, New York, NY, United States, 10118 |
| Phone | 431 890 6360 |
| Web | https://www.hookipapharma.com |
Hookipa Pharma Management Efficiency
The company has return on total asset (ROA) of (0.201) % which means that it has lost $0.201 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4899) %, meaning that it created substantial loss on money invested by shareholders. Hookipa Pharma's management efficiency ratios could be used to measure how well Hookipa Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.53. The value of Return On Capital Employed is expected to slide to -0.86. At this time, Hookipa Pharma's Non Current Liabilities Other is quite stable compared to the past year. Change To Liabilities is expected to rise to about 4.5 M this year, although the value of Total Current Liabilities will most likely fall to about 25.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Gregory Flesher | Eledon Pharmaceuticals | 54 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| MS MBA | Inozyme Pharma | 47 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| Joshua Cohen | Amylyx Pharmaceuticals | 32 | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Demetrios MD | Inozyme Pharma | N/A | |
| Shauna Horvath | Amylyx Pharmaceuticals | N/A | |
| Chris Aiello | Amylyx Pharmaceuticals | N/A | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Keith MD | X4 Pharmaceuticals | 53 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Murray MD | X4 Pharmaceuticals | 63 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| Margaret MBA | Amylyx Pharmaceuticals | 59 | |
| MBA MBA | Mereo BioPharma Group | 67 | |
| Tom Holmes | Amylyx Pharmaceuticals | N/A | |
| Eric MD | Acumen Pharmaceuticals | 69 | |
| Debra Canner | Amylyx Pharmaceuticals | 65 | |
Management Performance
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.2 |
Hookipa Pharma Leadership Team
Elected by the shareholders, the Hookipa Pharma's board of directors comprises two types of representatives: Hookipa Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hookipa. The board's role is to monitor Hookipa Pharma's management team and ensure that shareholders' interests are well served. Hookipa Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hookipa Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lukas Flatz, CoFounder | ||
| Klaus Orlinger, Chief Officer | ||
| Reinhard Kandera, CFO Director | ||
| Matthew Beck, Executive Relations | ||
| Mark Winderlich, Chief Officer | ||
| Joern Aldag, CEO Director | ||
| Marine Popoff, Communications Mang | ||
| Michael Szumera, Executive Communications | ||
| Roman Necina, Chief Officer | ||
| Prof MD, CoFounder | ||
| Andreas Bergthaler, CoFounder | ||
| Christine MBA, Chief Officer | ||
| Daniel Courtney, Corporate Secretary | ||
| Malte MD, CEO Director | ||
| Mary MBA, CFO VP |
Hookipa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hookipa Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.93) % | ||||
| Operating Margin | (17.37) % | ||||
| Current Valuation | (31.01 M) | ||||
| Shares Outstanding | 9.66 M | ||||
| Shares Owned By Insiders | 21.43 % | ||||
| Shares Owned By Institutions | 37.16 % | ||||
| Number Of Shares Shorted | 36.24 K | ||||
| Price To Earning | 12.06 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.67) | Revenue Per Share 4.403 | Quarterly Revenue Growth (0.52) | Return On Assets (0.20) | Return On Equity (0.49) |
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.